Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.
Date
2011Author
Castellano, D. E.
Bodrogi, I.
Booth, J. L.
Rosamilia, M.
Yuan, R. R.
Hawkins, R.
Knox, J. J.
Blank, C. U.
Gruenwald, V.
Karakiewicz, P. I.
Bavbek, S. E.
Miller, K.
Machiels, J. H.
Lee, S.
Larkin, J. M. G.
Bono, P.
Rha, S. Y.
Metadata
Show full item recordCollections
- Makale [92796]